A Prospective Trial in Patients With Crohn's Disease in Remission and Having Irritable Bowel Syndrome-like Symptoms

Inclusion Criteria

• •Male and female patients aged from 18 years to 75 years,
• •Long standing (\>3 months prior to V1) steroid-free clinical remission Crohn's disease according to clinical and biochemical assessments,
• •Clinical remission (according to the investigator),
• •Absence of inflammatory markers at V1,
• •Presence of IBS-like symptoms according to Rome IV criteria,
• •Likert scale ≥ 3 for abdominal pain at V0,
• •Patient with correct and complete reporting of the study questionnaires and scores during the run-in period (≥ 75% completion),
• •To continue all medication used in the last month before inclusion at the same dosage,
• •Anti-spasmodic, hypomotility agents, probiotics, prebiotics, bile-acid chelators, and anti-depressants are authorized if consumed for longer than 1 month before inclusion and maintained at a stable dosage for the entire study duration,
• •Agreeing to maintain their lifestyle behaviours during the participation in the study,
• •Patient has read, understood, and signed the informed consent form (ICF),
• •Patients capable of communicating with the investigator, replying to the questionnaires, and understanding the requirements and constraints of the study protocol,
• •Possession of a digital device (i.e., smartphone or tablet),
• •Patient willing to adhere to the study visit schedule and able to understand and comply with protocol requirements and product administration,
• •Male or female patient of childbearing potential who agrees to use acceptable methods of birth control (oral, transdermal, systemic contraception, intrauterine device, condom) for the duration of the study,
• •Patient can read and write in French.